Compositions and methods for detecting viral nucleic acids
AssigneeArizona Board of Regents on behalf of Arizona State University
InventorsShengxi Chen, Sidney Hecht, Mingxuan Gao
Life of this patent
Estimating the term…
Abstract
Described herein are compositions that may be used to detect viral nucleic acid. For example, these compositions may comprise a DNA-nanostructure, a capture oligonucleotide and a protector oligonucleotide, wherein the components are designed based on a duo-toehold-mediated displacement reaction (duo-TMDR) strategy. In this strategy, a first TMDR can switch off a Faster resonance energy transfer (FRET) process and a second TMDR can release the target viral nucleic acid and amplify the signal. Methods of using such compositions are also provided herein.
Claims9
A DNA nanostructure comprising four DNA oligonucleotides, wherein the first oligonucleotide has the sequence of SEQ ID NO:
- 2, the second oligonucleotide has the sequence of SEQ ID NO:
- 3, the third oligonucleotide has the sequence of SEQ ID NO:
- 4, and the fourth oligonucleotide has a length of 30 to 80 nucleotides and comprises a sequence that is at least 95% complementary to a target viral nucleic acid sequence;
- wherein the DNA nanostructure is a DNA tetrahedron comprising five double-stranded edges and one single-stranded edge;
- and
- wherein the target viral nucleic acid sequence is a sequence from a virus selected from dengue virus, Ebola virus, human immunodeficiency virus (HIV), hepatitis B, hepatitis C, influenza, measles, Zika, yellow fever, West Nile fever, smallpox, Marburg viruses, human papillomavirus, Kaposi's sarcoma-associated herpesvirus, and human T-lymphotropic virus.
A kit comprising:
- (a) a DNA nanostructure comprising four DNA oligonucleotides, wherein the first oligonucleotide has the sequence of SEQ ID NO:
- 2, the second oligonucleotide has the sequence of SEQ ID NO:
- 3, the third oligonucleotide has the sequence of SEQ ID NO:
- 4, and the fourth oligonucleotide has a length of 30 to 80 nucleotides and comprises a sequence that is complementary to a target viral nucleic acid;
- wherein the DNA nanostructure is a DNA tetrahedron comprising five double-stranded edges and one single-stranded edge;
- and
- wherein the target viral nucleic acid is from a virus selected from dengue virus, Ebola virus, human immunodeficiency virus (HIV), hepatitis B, hepatitis C, influenza, measles, Zika, yellow fever, West Nile fever, smallpox, Marburg viruses, human papillomavirus, Kaposi's sarcoma-associated herpesvirus, and human T-lymphotropic virus;
- (b) a protector oligonucleotide;
- and
- (c) a capture oligonucleotide;
- wherein:
- the protector oligonucleotide is 15 to 25 nucleotides in length, is capable of hybridizing to the fourth oligonucleotide;
- and is operably linked to a fluorophore or a quencher;
- the target viral nucleic acid is capable of displacing the protector oligonucleotide and hybridizing to the DNA tetrahedron;
- and
- the capture oligonucleotide is 15 to 30 nucleotides in length and is capable of displacing the target viral nucleic acid and hybridizing to the DNA tetrahedron, but is not capable of displacing the protector oligonucleotide.
Dependencies are inferred from the claim text.